大成生化科技(00809.HK):旗下哈尔滨大成暂停生产
大成生化科技(00809.HK)公布,经考虑自2018年起亚洲爆发非洲猪瘟,导致市场景气低迷,持续拖累玉米提炼行业表现,加上集团营运资金紧张,管理层已决定暂停间接全资附属公司哈尔滨大成的生产。
哈尔滨大成主要从事玉米淀粉、蛋白粉、玉米油及其他玉米提炼产品的生产及销售。哈尔滨大成的营业额及净亏损分别占集团截至6月底止六个月总营业额13%及净亏损8.8%。
董事会认为,停产能减少经营现金流出及确保集团有充足资源投放於其他核心业务活动,故此举符合公司及股东的整体最佳利益。预期停产不会对集团截至2019年12月31日止年度的财务状况造成任何重大不利影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.